Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as ...

Sutro Biopharma (STRO) announced the completion of a strategic portfolio review resulting in the prioritization of its three wholly-owned ...

Sutro completed its review as it widened its loss and posted lower revenue in 2024. The company posted a loss of $227.5 million last year, compared with a loss of $106.8 million in 2023. On a ...

The Lyon County Sheriff's Office is investigating an attempted child luring incident that occurred near Sutro Elementary ...

You may not be able to swim in this architectural wonder, but its beauty and coastal views are more than reason enough to add ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel ...

TimesMachine is an exclusive benefit for home delivery and digital subscribers. Full text is unavailable for this digitized archive article. Subscribers may view the full text of this article in ...

March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company ... of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will ...

Sutro Tower, as rendered by Vincent Woo. If you’ve lived in San Francisco for a while, you may have gotten curious about the big red triangular tower at the top of Twin Peaks. Most of us know that ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage ...